Group 1 - The company, Capbio, announced that it received a notification from its major shareholder, Yunnan Zhonghe Enterprise Management Co., Ltd., regarding the pledge of shares [1] - Yunnan Zhonghe will be lifting the pledge on 1.045 million shares, which represents 2.60% of its holdings in the company and 0.17% of the total share capital [1]

Group 1 - The company, Guangdong Cap Bio-Tech Co., Ltd., announced that its major shareholder, Yunnan Zhonghezhi Enterprise Management Co., Ltd., will lift the pledge of 1.045 million shares to Hongta Securities Co., Ltd. [1] - As of the announcement date, Yunnan Zhonghezhi has pledged a total of 26.975 million shares, accounting for 4.3% of the company's total share capital [1]

Core Viewpoint - The company, Capbio, announced that its major shareholder, Yunnan Zhonghe Enterprise Management Co., Ltd., will release the pledge of 1.045 million shares to Hongta Securities Co., Ltd. [1] Summary by Relevant Sections Shareholder Actions - Yunnan Zhonghe will release 1.045 million shares, which represents 2.60% of its total holdings in the company and 0.17% of the company's total share capital [1] - After the release of the pledge, Yunnan Zhonghe holds a total of 40,147,564 shares in the company [1] Pledged Shares - The total number of pledged shares by Yunnan Zhonghe amounts to 26.975 million shares, which is 67.19% of its total holdings and 4.30% of the company's total share capital [1]

证券代码：300639 证券简称：凯普生物 公告编号：2025-069 股东名称 是否为第 一大股东 及一致行 动人 本次解除 质押股数 （万股） 占其所 持股份 比例(%) 占公司 总股本 比例 (%) 质押开 始日期 解除质 押日期 质权人 云南众合 之 否 104.50 2.60 0.17 2023 年 12月6日 2025 年 12月2日 红塔证 券 一、股东部分股份解除质押的基本情况 | | | 占公 | | 占其所 | 占公 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 名称 | 持股数量 （股） | 司总 股本 比例 | 累计被质 押数量 （万股） | 持公司 股份比 | 司总 股本 比例 | 已质押股 份限售和 冻结、标 | 占已质 押股份 | 未质押 股份限 售和冻 | 占未 质押 | | | | | | 例（%） | | | 比例 | | 股份 | | | | （%） | | | （%） | 记数量 | （%） | 结数量 | 比例 | | | | | ...

证券代码：300639 证券简称：凯普生物 公告编号：2025-068 广东凯普生物科技股份有限公司 断目前主要依赖于基因检测，因而基因检测过程的质量控制尤为关键。高质量的阳 性质控品是保障基因检测结果准确性与可靠性的重要基础。本公司发明专利"一种 脊髓性肌萎缩症质控品及其制备方法和应用"属于细胞工程与基因检测技术领域。 该发明公开了一种用于 SMA 基因检测的质控品及其构建与应用策略。针对目前利用 EB 病毒永生化淋巴细胞方法存在的转化效率低等问题，本发明提供了一种新型转化 培养基及相应的高效构建永生化 SMA 淋巴细胞的方法。采用本发明所述方法，可在 30 天内成功构建永生化脊髓性肌萎缩症淋巴细胞株，并通过传代培养获得稳定的永 生化细胞系。该方法不仅构建周期短、成功率显著提高，所得细胞株还具有遗传背 景稳定、与临床样本互通性强、兼容性良好以及可长期稳定保存等优势。因此，该 细胞株适合作为阳性质控品应用于 SMA 的基因检测过程中，有助于确保检测结果的 准确性与一致性。 公司持续向"核酸分子诊断龙头企业"的大目标迈进，持续推进"核酸 99"战 略，促进公司产品结构的不断丰富，满足市场多样化的需求。上述发明专 ...

证券代码：300639 股票简称：凯普生物 公告编号：2025-067 广东凯普生物科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，广东凯普生物科技股份有限公司全资子公司潮州凯普生物化学有限公 司收到了广东省药品监督管理局颁发的《医疗器械生产许可证》，主要涉及生产 范围的变更。本次变更后的医疗器械生产许可证具体内容如下： 许可证编号：粤食药监械生产许20041040号 企业名称：潮州凯普生物化学有限公司 住 所：广东省潮州市经济开发试验区北片高新区D5-3-3-4 统一社会信用代码：91445100761585197P 法定代表人：谢龙旭 企业负责人：翁丹容 生产地址：广东省潮州市经济开发试验区北片高新区D5-3-3-4;潮州市湘桥 区创北路1号凯普综合楼第四层、第五层、第六层B区 关于全资子公司变更医疗器械生产许可证的公告 生产范围：Ⅲ类6840体外诊断试剂。 Ⅱ类18妇产科、辅助生殖和避孕器械,Ⅱ类22临床检验器械。 有效期至：2029年1月8日 特此公告！ 广东凯普生物科技股份有限公司董事会 二○二五年十一月二十八日 ...

Core Viewpoint - Capbio announced that its wholly-owned subsidiary, Chaozhou Capbio Biochemical Co., Ltd., has received a Medical Device Manufacturing License from the Guangdong Provincial Drug Administration, indicating a change in production scope [1] Group 1: License Details - The license number is粤食药监械生产许20041040, which includes the production scope of Class III in vitro diagnostic reagents, Class II obstetrics and gynecology, assisted reproduction, and contraceptive devices, as well as Class II clinical testing devices [1] - The license is valid until January 8, 2029 [1]

Core Viewpoint - Capbio (300639) reported that as of November 20, 2025, the total number of shareholders is 27,778 [1] Summary by Category - **Company Information** - Capbio has a total of 27,778 shareholders as of the specified date [1]

Core Insights - The medical testing industry is facing significant challenges due to increased accounts receivable and declining profits, particularly following the COVID-19 pandemic [1][4][5] Group 1: Accounts Receivable and Financial Performance - Four companies have accounts receivable exceeding 2 billion yuan, with Capbio (凯普生物) involved in lawsuits to recover 357 million yuan in overdue payments [1] - In the first three quarters of this year, at least seven medical testing companies reported net losses attributable to shareholders, with six of them expected to continue this trend into 2024 [1] - Specific losses reported include: Puni Testing (谱尼测试) at 199 million yuan, RunDa Medical (润达医疗) at 163 million yuan, and Capbio at 128 million yuan [1] Group 2: Impact of Price Reductions and Impairment Provisions - Price reductions in the testing sector have led to widespread profit shrinkage among medical testing companies, with some firms making impairment provisions for accounts receivable [4] - Companies like KingMed Diagnostics (金域医学) have made significant impairment provisions, totaling 345 million yuan, primarily for accounts receivable, which reduced their consolidated profit by the same amount [4] - Lanwei Medical (兰卫医学) reported a total impairment provision of 16.73 million yuan, with 13.50 million yuan specifically for accounts receivable [5] Group 3: Recovery Trends and Future Outlook - The Ministry of Finance has indicated a commitment to debt reduction policies, which may accelerate the collection of accounts receivable from public hospitals [5] - Companies are implementing strategies to manage accounts receivable more effectively, with Puni Testing focusing on tailored collection strategies for major clients [6] - DiAn Diagnostics (迪安诊断) anticipates improved collection trends in the second half of the year, with expectations that all COVID-related accounts receivable will be fully provisioned by year-end [5][6]

Core Points - The company, Capstone Bio (300639), reported that as of October 30, 2025, the total number of shareholders is 28,450 [1]